Get the Stockscreener App
2.12
0.95%
0.02
Overview
News
Price History
Option Chain
Financials
Why SAVA Down?
Discussions
Forecast
Stock Split
Dividend History
Cassava Sciences Inc stock is traded at $2.12, with a volume of 547.12K.
It is up +0.95% in the last 24 hours and up +14.59% over the past month.
Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease; and investigational diagnostic product candidate is called SavaDx and it is a novel way to detect the presence of Alzheimer's disease from a small sample of blood, possibly years before the overt appearance of clinical symptoms. It is currently conducting two randomized placebo-controlled Phase 3 clinical trials of oral simufilam in patients with Alzheimer's disease dementia. It has one business segment: the development of novel drugs and diagnostics.
See More
Previous Close:
$2.10
Open:
$2.1
24h Volume:
547.12K
Relative Volume:
0.54
Market Cap:
$102.41M
Revenue:
-
Net Income/Loss:
$-97.22M
P/E Ratio:
-1.5362
EPS:
-1.38
Net Cash Flow:
$-82.44M
1W Performance:
-9.79%
1M Performance:
+14.59%
6M Performance:
-10.92%
1Y Performance:
-90.97%
1-Day Range:
$2.05
$2.17
1-Week Range:
$2.05
$2.49
52-Week Range:
$1.15
$42.20
Cassava Sciences Inc Stock (SAVA) Company Profile
Name
Cassava Sciences Inc
Sector
Industry
Phone
512-501-2444
Address
6801 N CAPITAL OF TEXAS HIGHWAY, AUSTIN, TX
Compare SAVA with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
SAVA
Cassava Sciences Inc
|
2.12 | 101.45M | 0 | -97.22M | -82.44M | -1.38 |
|
VRTX
Vertex Pharmaceuticals Inc
|
462.13 | 117.32B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
558.87 | 58.89B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
401.80 | 51.14B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
673.80 | 41.02B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
299.01 | 32.59B | 3.81B | -644.79M | -669.77M | -6.24 |
Cassava Sciences Inc Stock (SAVA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-26-24 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Oct-08-24 | Upgrade | H.C. Wainwright | Neutral → Buy |
| Jul-01-24 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Nov-16-22 | Downgrade | B. Riley Securities | Buy → Neutral |
| Jul-15-21 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| Jul-07-21 | Reiterated | Maxim Group | Buy |
| Apr-27-21 | Initiated | B. Riley Securities | Buy |
| Feb-16-21 | Reiterated | H.C. Wainwright | Buy |
| Oct-23-20 | Initiated | Cantor Fitzgerald | Overweight |
| Sep-23-20 | Upgrade | H.C. Wainwright | Neutral → Buy |
| May-18-20 | Downgrade | H.C. Wainwright | Buy → Neutral |
| May-15-20 | Downgrade | Maxim Group | Buy → Hold |
| Jan-10-20 | Reiterated | Maxim Group | Buy |
View All
Cassava Sciences Inc Stock (SAVA) Latest News
Should I hold or sell Cassava Sciences Inc. stock in 2025Smart Portfolio Strategy With High Returns - jammulinksnews.com
What catalysts could drive Cassava Sciences Inc. Equity Warrant stock higher in 2025Free Stock Trend Scanner With Proven Results - jammulinksnews.com
What makes Cassava Sciences Inc. Equity Warrant stock price move sharplyMarket Forecast Review For 2025 - jammulinksnews.com
What is the risk reward ratio of investing in Cassava Sciences Inc. stockPost Market Updates For Consistent Profits - jammulinksnews.com
What is Cassava Sciences Inc. Equity Warrant company’s growth strategyPre Market Entry Points To Watch Now - jammulinksnews.com
Using Bollinger Bands to evaluate Cassava Sciences Inc. Equity WarrantExpert Verified Stock Trade Ideas Backed by Data - metal.it
What is the dividend policy of Cassava Sciences Inc. stockMarket Forecast Picks That Work - jammulinksnews.com
SAVA INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Reminds Investors of Cassava Sciences, Inc. to Contact the Firm Today! - ACCESS Newswire
Published on: 2025-07-30 22:25:23 - metal.it
Short Covering May Lift Cassava Sciences Inc. in Near TermWeekly Stock Watch With Growth Focus Expanded - metal.it
Why Cassava Sciences Inc. Equity Warrant stock attracts strong analyst attentionValue Investing Picks With Stability Outlined - metal.it
Is Cassava Sciences Inc. Equity Warrant a Top Dividend Stock to Watch in 2025Daily Chart Pattern Stock Forecast Shows Bullish Setup - metal.it
Relief Rally in Cassava Sciences Inc. Equity Warrant Stock — Can It HoldSecure Return Focused Investment Plan Released - metal.it
Cassava Sciences Inc. Equity Warrant At Decision Level — Rebound or ResistanceBeginner Friendly Stock Selection Guide Updated - metal.it
Published on: 2025-07-29 16:03:06 - metal.it
Cassava Sciences Inc. Stock Chart Analysis: Bullish or Bearish Pattern FormingProfit Target Stock Opportunity Monitor Activated - beatles.ru
Published on: 2025-07-29 07:25:41 - beatles.ru
How does Cassava Sciences Inc. compare to its industry peersBest Dividend Data Feed Backed By Experts - jammulinksnews.com
Can a trend reversal in Cassava Sciences Inc. Equity Warrant lead to recoveryCapital Efficiency Optimized Stock Alerts Reviewed - metal.it
Published on: 2025-07-28 20:31:45 - metal.it
What catalysts could drive Cassava Sciences Inc. stock higher in 2025Wealth Building Opportunities For Beginners - jammulinksnews.com
What are the technical indicators suggesting about Cassava Sciences Inc. Equity WarrantRealize consistent double-digit growth - jammulinksnews.com
Is Cassava Sciences Inc. Equity Warrant a growth stock or a value stockExplosive portfolio gains - jammulinksnews.com
Is Cassava Sciences Inc. Equity Warrant stock overvalued or undervaluedSkyrocketing returns - jammulinksnews.com
Key External Factors That Drive Cassava Sciences Inc. Stock Price MovementsTop Performing Low Risk Stocks - metal.it
What institutional investors are buying Cassava Sciences Inc. stockInvest confidently with expert support - jammulinksnews.com
Published on: 2025-07-28 00:53:57 - jammulinksnews.com
Why is Cassava Sciences Inc. Equity Warrant stock attracting strong analyst attentionBuild a portfolio that grows with the market - jammulinksnews.com
What drives Cassava Sciences Inc. stock priceDynamic portfolio growth - PrintWeekIndia
Cassava Sciences Inc. Equity Warrant Stock Analysis and ForecastSuperior investment outcomes - PrintWeekIndia
Will Cassava Sciences Inc. Equity Warrant stock benefit from AI tech trendsMarket-leading growth rates - jammulinksnews.com
Cassava Sciences Inc. Stock Analysis and ForecastRecord-breaking gains - Autocar Professional
What analysts say about Cassava Sciences Inc. Equity Warrant stockOverwhelming financial success - PrintWeekIndia
Is Cassava Sciences Inc. a good long term investmentRecord-breaking gains - Autocar Professional
Is Cassava Sciences Inc. Equity Warrant a good long term investmentFree Trend-Following Techniques - jammulinksnews.com
What analysts say about Cassava Sciences Inc. stockBreakthrough profit margins - jammulinksnews.com
What drives Cassava Sciences Inc. Equity Warrant stock priceFree Stock Market Real-Time Monitoring - jammulinksnews.com
Cassava Sciences Inc Stock (SAVA) Financials Data
Revenue
Net Income
Cash Flow
EPS
Cassava Sciences Inc Stock (SAVA) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Schoen Eric | Chief Financial Officer |
Nov 29 '24 |
Option Exercise |
1.18 |
50,000 |
59,000 |
71,300 |
| Schoen Eric | Chief Financial Officer |
Nov 29 '24 |
Sale |
3.86 |
59,800 |
230,828 |
11,500 |
| Schoen Eric | Chief Financial Officer |
Nov 29 '24 |
Sale |
3.82 |
2,000 |
7,640 |
0 |
0.93%
0.15%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):